Cetuximab

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9747 publications

Extensive Subcutaneous Hematoma in a Patient Receiving Nigella sativa Oil, Dual Antiplatelet Therapy, and Oxaliplatin-Based Chemotherapy: A Case Report.

Extensive Subcutaneous Hematoma in a Patient Receiving Nigella sativa Oil, Dual Antiplatelet Therapy, and Oxaliplatin-Based Chemotherapy: A Case Report.

Journal: Hospital pharmacy
Published: September 02, 2026

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

Journal: ESMO gastrointestinal oncology
Published: August 28, 2026

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 27, 2026

Ras homolog family member A expression is associated with reduced cetuximab sensitivity in head and neck squamous cell carcinoma.

Ras homolog family member A expression is associated with reduced cetuximab sensitivity in head and neck squamous cell carcinoma.

Journal: The Journal of international medical research
Published: August 24, 2026

Experimental and computational analyses of altered cetuximab binding induced by EGFR mutations

Experimental and computational analyses of altered cetuximab binding induced by EGFR mutations

Journal: Sheng wu gong cheng xue bao = Chinese journal of biotechnology
Published: August 24, 2026

Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands.

Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands.

Journal: ESMO gastrointestinal oncology
Published: August 12, 2026

O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation-Guided Irinotecan-Based Therapy in Metastatic Colorectal Cancer: A Case Report.

O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation-Guided Irinotecan-Based Therapy in Metastatic Colorectal Cancer: A Case Report.

Journal: Cureus
Published: July 21, 2026

WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.

WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.

Journal: Oncotarget
Published: July 21, 2026

Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

Journal: Cancer chemotherapy and pharmacology
Published: July 18, 2026

Durable Complete Response Following Nivolumab Discontinuation in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma Complicated by Bullous Pemphigoid: A Case Report.

Durable Complete Response Following Nivolumab Discontinuation in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma Complicated by Bullous Pemphigoid: A Case Report.

Journal: Cureus
Published: July 14, 2026

Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab.

Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab.

Journal: Cell reports
Published: July 13, 2026

RAF/MEK Clamp Inhibition with Avutometinib and Cetuximab in RAF1 S257L-Mutated, Anti-EGFR-Refractory Metastatic Colorectal Cancer in Gaucher's disease.

RAF/MEK Clamp Inhibition with Avutometinib and Cetuximab in RAF1 S257L-Mutated, Anti-EGFR-Refractory Metastatic Colorectal Cancer in Gaucher's disease.

Journal: The oncologist
Published: July 08, 2026
Showing 1-12 of 9,747

Last Updated: 09/26/2026